Long-term efficacy of netakimab in the treatment of radiographic axial spondyloarthritis: Results of a systematic review and simulated indirect comparisons

The aim – to compare the long-term efficacy of netakimab with other registered drugs in the Russian Federation to treat radiographic axial spondyloarthritis over a period of up to 3 years.

Materials and methods. A systematic literature search was conducted in PubMed and Embase databases. 19 publications evaluating the results of 11 clinical trials were selected. The simulated treatment comparison method according to NICE DSU TSD 18 (National Institute for Health and Care Excellence Decision Support Unit Technical Support Document 18) recommendations was used for comparison. Age, sex, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), ASDAS (Ankylosing Spondylitis Disease Activity Score), C-reactive protein, disease duration since axial spondyloarthritis diagnosis, and HLA-B27 status were selected as confounding variables for adjustment.

Results. Netakimab demonstrated superiority over all interleukin 17 and tumor necrosis factor α (TNF-α) inhibitors, as well as tofacitinib, on the main efficacy endpoints ASAS20 and ASAS40 (20% and 40% improvement according to the Assessment of SpondyloArthritis international Society criteria) over a period of up to 3 years. No superiority was detected compared to upadacitinib.

Conclusion. Netakimab is one of the most superior therapeutic option among available biologics for long-term treatment of active axial spondyloarthritis. Using netakimab as the first-line or second-line therapy allows achieving treatment goals with the highest probability. The results are useful for evidence-based clinical decision-making when choosing biological therapy considering patient profile and can be used for planning treatment strategy after TNF-α inhibitor failure.

1. Lila AM, Dubinina TV, Dreval RO, Lapshina SА, Zabotina AN. Medical and social significance and calculation of the economic burden of axial spondyloarthritis in the Russian Federation. Modern Rheumatology Journal. 2022;16(1):20-25 (In Russ.) doi: 10.14412/1996-7012-2022-1-20-25

2. Axial Spondyloarthritis International Federation (ASIF) statement on disease burden: “Unacceptable delay in diagnosis of axial spondyloarthritis (axSpA): A common call to action”. 2021 (In Russ.). URL: https://asif.info/wp-content/uploads/2022/03/MF_ASIF_DD_report_v17_ru-RU_HiRes.pdf. (Accessed: 10th October 2025).

3. Gaydukova I, Garrido-Cumbrera M, Dubinina T, Dubikov A, Zonova E, Korolev M, et al. Impact of axSpA on working life: Results from 233 patients of the Russian Federation participating in the European Map of Axial Spondyloarthirtis (EMAS). Ann Rheum Dis. 2020;79:1638. doi: 10.1136/annrheumdis-2020-eular.4875

4. Yushina ES, Zonova EV. Advanced axial spondyloarthritis: Delayed diagnosis and identification of potential predictors of disease progression. Journal of Siberian Medical Sciences. 2024;(3):136-153 (In Russ.). doi: 10.31549/2542-1174-2024-8-3-136-153

5. The economics of disability: How to count patients. Expert. 2021 Dec 03 (In Russ.). URL: https://expertnw.com/ekonomika/ekonomika-invalidizatsii-kak-schitat-patsientov (Accessed: 17th October 2025).

6. Erdes ShF, Dubinina TV. Recommendations for the treatment of axial spondyloarthritis: An analysis of the updated ASAS/EULAR 2022 clinical guidelines. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(2):129-137 (In Russ.). doi: 10.47360/19954484-2025-129-137

7. Pozharov IV, Akimova ES. Survival rate of patients with ankylosing spondylitis during biological and targeted therapy in clinical practice. RMJ. 2024;3:16-21 (In Russ.).

8. Dubinina TV, Gaydukova IZ, Sokolova VD, Mladov VV, Tolkacheva DG. Efficacy and safety of biologics for the treatment of ankylosing spondylitis: Systematic literature review and network meta-analysis of treatments registered in the Russian Federation. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(6):646-657 (In Russ.). doi: 10.47360/1995-4484-2020-646-657

9. Mazurov VI, Erdes SF, Gaydukova IZ, Dubinina TV, Pristrom AM, Kunder EV, et al. Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: Results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ ASTERA. Modern Rheumatology Journal. 2024;18(1):35-46 (In Russ.). doi: 10.14412/1996-7012-2024-1-35-46

10. European Medicines Agency. Guideline on the clinical investigation of medicinal products for the treatment of axial spondyloarthritis. 2018. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinalproducts-treatment-axial-spondyloarthritis-revision-1_en.pdf (Accessed: 17th October 2025).

11. Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. (Technical Support Documents). NICE Decision Support Unit. 2016. URL: https://www.nicedsu.org.uk/Populationadjusted-ICsTSD(3026862).htm (Accessed: 17th October 2025).

12. Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200-211. doi: 10.1177/0272989X17725740

13. Ishak KJ, Proskorovsky I, Benedict A. Simulation and matchingbased approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537-549. doi: 10.1007/s40273-015-0271-1

14. Remiro-Azócar A, Heath A, Baio G. Parametric G-computation for compatible indirect treatment comparisons with limited individual patient data. Res Synth Methods. 2022;13(6):716-744. doi: 10.1002/jrsm.1565

15. Zhang L, Bujkiewicz S, Jackson D. Four alternative methodologies for simulated treatment comparison: How could the use of simulation be re-invigorated? Res Synth Methods. 2024;15(2):227-241. doi: 10.1002/jrsm.1681

16. Ren S, Ren S, Welton NJ, Strong M. Advancing unanchored simulated treatment comparisons: A novel implementation and simulation study. Res Synth Methods. 2024;15(4):657-670. doi: 10.1002/jrsm.1718

17. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70(6):973-981. doi: 10.1136/ard.2010.147744

18. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with antitumour necrosis factor: Results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69(11):2002-2008. doi: 10.1136/ard.2009.124446

19. Ørnbjerg LM, Linde L, Georgiadis S, Rasmussen SH, Lindström U, Askling J, et al. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration. Semin Arthritis Rheum. 2022;56:152081. doi: 10.1016/j.semarthrit.2022.152081

20. Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: Pooled analysis from large randomized clinical trials. J Rheumatol. 2015;42(8):1418-1426. doi: 10.3899/jrheum.141278

21. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL; BSR Biologics Register. Predictors of response to antiTNF therapy in ankylosing spondylitis: Results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49(3):563-570. doi: 10.1093/rheumatology/kep422

22. Sakr BR, Mohamed HE, Effat DA. Relationship of adherence to treatment with disease activity, physical function, quality of life, treatment satisfaction and beliefs in axial spondyloarthritis patients. Egypt Rheumatol. 2022;44(3):191-195. doi: 10.1016/j.ejr.2021.12.001

23. Thomassen EEK, Berg IJ, Kristianslund EK, Tveter AT, Bakland G, Gossec L, et al. Patients with axial spondyloarthritis reported willingness to use remote care and showed high adherence to electronic patient-reported outcome measures: An 18-month observational study. Rheumatol Int. 2024;44(10):2089-2098. doi: 10.1007/s00296-024-05673-7

24. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13(3):R94. doi: 10.1186/ar3369

25. Murray GD, Barer D, Choi S, Fernandes H, Gregson B, Lees KR, et al. Design and analysis of phase III trials with ordered outcome scales: The concept of the sliding dichotomy. J Neurotrauma. 2005;22(5):511-517. doi: 10.1089/neu.2005.22.511

26. Cario MC, Nelson BL. Modeling and generating random vectors with arbitrary marginal distributions and correlation matrix (Technical Report, Department of Industrial Engineering and Management Sciences, Northwestern University, Evanston, IL). 1997. URL: https://www.ressourcesactuarielles.net/EXT/ISFA/1226.nsf/0/5d499a3efc8ae4dfc125756c00391ca6/$FILE/NORTA.pdf (Accessed: 17th October 2025).

27. Mazurov VI, Gaydukova IZ, Erdes Sh, Dubinina TV, Pristrom AM, Kunder EV, et al. Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(4):376-386 (In Russ.). doi: 10.47360/19954484-2020-376-386

28. Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71(5):661-667. doi: 10.1136/ard.2011.154799

29. Inman RD, Davis JC Jr, Heijde Dv, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402-3412. doi: 10.1002/art.23969

30. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003;48(8):2224-2233. doi: 10.1002/art.11104

31. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford). 2005;44(5):670-676. doi: 10.1093/rheumatology/keh584

32. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years – early clinical response predicts long-term outcome. Rheumatology (Oxford). 2011;50(9):16901699. doi: 10.1093/rheumatology/ker194

33. Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(5):700-706. doi: 10.1136/annrheumdis-2011-200358

34. Tu L, Zhao M, Wang X, Kong Q, Chen Z, Wei Q, et al. Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial. Front Immunol. 2022;13:967658. doi: 10.3389/fimmu.2022.967658

35. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebocontrolled Phase 3 study. Ann Rheum Dis. 2014;73(1):39-47. doi: 10.1136/annrheumdis-2013-204231

36. Van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017;56(9):1498-1509. doi: 10.1093/rheumatology/kex174

37. Marzo-Ortega H, Sieper J, Kivitz AJ, Blanco R, Cohen M, Pavelka K, et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: End-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020;2(6):e339-e346. doi: 10.1016/S2665-9913(20)30066-7

38. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al.; MEASURE 1 Study Group; MEASURE 2 Study Group. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534-2548. doi: 10.1056/NEJMoa1505066

39. van der Heijde D, Deodhar A, Maksymowych WP, Sieper J, van den Bosch F, Kim TH, et al. Upadacitinib in active ankylosing spondylitis: Results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open. 2022;8(2):e002280. doi: 10.1136/rmdopen-2022-002280

40. van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):21082117. doi: 10.1016/S0140-6736(19)32534-6

41. Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601

42. Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al.; COAST-W Study Group. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial spondyloarthritis: Sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599-611. doi: 10.1002/art.40753

43. de Vlam K, Maksymowych WP, Gallo G, Rahman P, Mease P, Krishnan V, et al. Exploring the effects of ixekizumab on pain in patients with ankylosing spondylitis based on objective measures of inflammation: Post hoc analysis from a large randomized clinical trial. Rheumatol Ther. 2024;11(3):691-707. doi: 10.1007/s40744-024-00660-7

44. Deodhar A, Poddubnyy D, Rahman P, Ermann J, Tomita T, Bolce R, et al. Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. J Rheumatol. 2023;50(8):1020-1028. doi: 10.3899/jrheum.221022

45. van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al.; COAST-V study group. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9

46. Dalix E, Goupille P, Wendling D, Roux C, Samon J, Brocq O, et al. Rotation or change of biologic after TNF blocker treatment failure for axial spondyloarthritis. Arthritis Rheumatol. 2025;77(Suppl 9). URL: https://acrabstracts.org/abstract/rotationor-change-of-biologic-after-tnf-blocker-treatment-failure-for-axial-spondyloarthritis/ (Accessed 12th May 2026).

47. Behrens F, Sternad P, Krueger K, App C, Lefevre S, Schiedel C. AgAIN study: First head-to-head trial of secukinumab vs. ustekinumab in TNFα inhibitor-experienced psoriatic arthritis patients reveals better efficacy across multiple domains. Arthritis Rheumatol. 2025;77(Suppl 9). URL: https://acrabstracts.org/abstract/againstudy-first-head-to-head-trial-of-secukinumab-vs-ustekinumabin-tnf%ce%b1-inhibitor-experienced-psoriatic-arthritis-patientsreveals-better-efficacy-across-multiple-domains (Accessed 12th May 2026).

48. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. Response to: Correspondence on :ASASEULAR recommendations for the management of axial spondyloarthritis: 2022 update: by Braun et al. Ann Rheum Dis. 2023;82(9):e206. doi: 10.1136/ard-2023-223937